NUVL – Nuvalent Inc
Nuvalent, Inc.NUVL
$123.25Name : Nuvalent, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $9,736,493,056.00
EPSttm : -6.06
Nuvalent, Inc.
$123.25
39.28%$34.76
NUVL — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
9.39
Margin Of Safety %
Put/Call OI Ratio
0.85
EPS Next Q Diff
-0.01
EPS Last/This Y
0.35
EPS This/Next Y
1.34
Price
123.22
Target Price
132.81
Analyst Recom
2.39
Performance Q
20.53
Upside
-272.1%
Beta
1.21
Ticker: NUVL
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-05-11 | NUVL | 104.47 | 1.10 | 0.00 | 1908 |
| 2026-05-12 | NUVL | 102.62 | 1.07 | 1.50 | 1934 |
| 2026-05-13 | NUVL | 105.4 | 1.07 | 999.99 | 1934 |
| 2026-05-14 | NUVL | 104.45 | 1.07 | 999.99 | 1935 |
| 2026-05-15 | NUVL | 102.31 | 1.07 | 0.25 | 1936 |
| 2026-05-18 | NUVL | 99.99 | 1.07 | 0.25 | 1936 |
| 2026-05-19 | NUVL | 101.02 | 0.70 | 0.00 | 1551 |
| 2026-05-20 | NUVL | 102.24 | 0.70 | 0.00 | 1552 |
| 2026-05-21 | NUVL | 101.12 | 0.70 | 0.43 | 1554 |
| 2026-05-22 | NUVL | 101.9 | 0.70 | 0.02 | 1568 |
| 2026-05-26 | NUVL | 104.87 | 0.67 | 0.17 | 1610 |
| 2026-05-27 | NUVL | 107.41 | 0.66 | 1.51 | 1642 |
| 2026-05-28 | NUVL | 109.3 | 0.71 | 0.00 | 1743 |
| 2026-05-29 | NUVL | 110.37 | 0.69 | 0.57 | 1765 |
| 2026-06-02 | NUVL | 91.34 | 0.94 | 0.74 | 2223 |
| 2026-06-03 | NUVL | 90.12 | 0.91 | 1.50 | 2291 |
| 2026-06-04 | NUVL | 93.92 | 0.90 | 0.00 | 2317 |
| 2026-06-05 | NUVL | 90.85 | 0.90 | 0.00 | 2315 |
| 2026-06-08 | NUVL | 88.49 | 0.86 | 0.00 | 2382 |
| 2026-06-09 | NUVL | 123.21 | 0.85 | 0.19 | 2389 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-05-11 | NUVL | 104.57 | -1.4 | - | -5.55 |
| 2026-05-12 | NUVL | 102.65 | 2.4 | - | -5.36 |
| 2026-05-13 | NUVL | 105.39 | 2.4 | - | -5.36 |
| 2026-05-14 | NUVL | 104.48 | 2.7 | - | -5.43 |
| 2026-05-15 | NUVL | 102.29 | 2.7 | - | -5.43 |
| 2026-05-18 | NUVL | 99.89 | 1.2 | - | -5.45 |
| 2026-05-19 | NUVL | 101.07 | 1.2 | - | -5.45 |
| 2026-05-20 | NUVL | 102.29 | 1.0 | - | -5.45 |
| 2026-05-21 | NUVL | 101.18 | 1.0 | - | -5.45 |
| 2026-05-22 | NUVL | 102.11 | 1.0 | - | -5.45 |
| 2026-05-26 | NUVL | 104.89 | 1.0 | - | -5.48 |
| 2026-05-27 | NUVL | 107.38 | 1.0 | - | -5.48 |
| 2026-05-28 | NUVL | 109.28 | 1.0 | - | -5.48 |
| 2026-05-29 | NUVL | 110.38 | 1.0 | - | -5.48 |
| 2026-06-01 | NUVL | 93.10 | 1.0 | - | -5.48 |
| 2026-06-02 | NUVL | 90.97 | 1.0 | - | -5.48 |
| 2026-06-03 | NUVL | 90.13 | 1.0 | - | -5.48 |
| 2026-06-04 | NUVL | 93.93 | 1.0 | - | -5.48 |
| 2026-06-05 | NUVL | 90.85 | 0.8 | - | -5.50 |
| 2026-06-08 | NUVL | 88.49 | 0.8 | - | -5.50 |
| 2026-06-09 | NUVL | 123.22 | 0.8 | - | -5.50 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-05-11 | NUVL | -3.98 | 7.03 | 8.80 |
| 2026-05-12 | NUVL | -3.98 | 7.03 | 9.71 |
| 2026-05-13 | NUVL | -3.98 | 7.03 | 9.71 |
| 2026-05-14 | NUVL | -3.98 | 7.03 | 9.71 |
| 2026-05-15 | NUVL | -3.98 | 7.03 | 9.71 |
| 2026-05-18 | NUVL | -3.98 | 6.85 | 9.70 |
| 2026-05-19 | NUVL | -3.98 | 6.85 | 9.70 |
| 2026-05-20 | NUVL | -3.82 | 6.85 | 9.70 |
| 2026-05-21 | NUVL | -3.82 | 6.85 | 9.70 |
| 2026-05-22 | NUVL | -3.82 | 6.85 | 9.70 |
| 2026-05-26 | NUVL | -1.19 | 2.51 | 9.70 |
| 2026-05-27 | NUVL | -1.17 | 2.51 | 9.70 |
| 2026-05-28 | NUVL | -1.17 | 2.51 | 9.40 |
| 2026-05-29 | NUVL | -1.17 | 2.51 | 9.40 |
| 2026-06-02 | NUVL | -1.21 | 1.93 | 9.39 |
| 2026-06-03 | NUVL | -1.19 | 1.93 | 9.39 |
| 2026-06-04 | NUVL | -1.24 | 1.93 | 9.39 |
| 2026-06-05 | NUVL | -1.24 | 1.93 | 9.39 |
| 2026-06-08 | NUVL | -1.24 | 1.93 | 9.39 |
| 2026-06-09 | NUVL | -1.24 | 1.93 | 9.39 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.39
Avg. EPS Est. Current Quarter
-1.38
Avg. EPS Est. Next Quarter
-1.4
Insider Transactions
-1.24
Institutional Transactions
1.93
Beta
1.21
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
1
Fair Value
Quality Score
9
Growth Score
23
Sentiment Score
46
Actual DrawDown %
-8.5
Max Drawdown 5-Year %
Target Price
132.81
P/E
Forward P/E
PEG
P/S
P/B
8.28
P/Free Cash Flow
EPS
-6.06
Average EPS Est. Cur. Y
-5.5
EPS Next Y. (Est.)
-4.16
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
77.39
Return on Equity vs Sector %
-65.8
Return on Equity vs Industry %
-49.6
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
◆
NUVL
Healthcare
$123.25
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
66.9
Range 1M
98.8%
Sup Dist
29.8%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
3.5%
EPS NY
22.9%
52W%
99.2%
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+7.8% upside
Upside
+7.8%
Quality
9
Nuvalent, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 234
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. Nuvalent, Inc. has a strategic partnership with Guardant Health, Inc. to develop companion diagnostics therapies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
NUVL
Latest News
—
Caricamento notizie per NUVL…
stock quote shares NUVL – Nuvalent Inc Stock Price stock today
news today NUVL – Nuvalent Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch NUVL – Nuvalent Inc yahoo finance google finance
stock history NUVL – Nuvalent Inc invest stock market
stock prices NUVL premarket after hours
ticker NUVL fair value insiders trading